1641-P: Prevalence of Metabolic Dysfunction–Associated Steatotic Liver Disease in Type 1 Diabetes Compared with Healthy Controls—A Cross-Sectional Study

• Published in: Diabetes (New York, N.Y.) Vol. 74; no. Supplement_1
• Main Authors: AMUEDO, SANDRA, BELLIDO, VIRGINIA, REMON-RUIZ, PABLO, ROQUE CUÉLLAR, MARÍA D.C., JIMÉNEZ SÁNCHEZ, ANDRÉS, GROS HERGUIDO, NOELIA, GALLARDO, GEMA, PIÑAR GUTIÉRREZ, ANA, ALFONSO, SOTO M.
• Format: Journal Article
• Language: English
• Published: 20.06.2025
• ISSN: 0012-1797
• DOI: 10.2337/db25-1641-P

Introduction and Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in people with T1D (PWT1D). We aimed to investigate the prevalence of MASLD in PWT1D using noninvasive biomarkers of hepatic steatosis and fibrosis and to compare these findings with a healthy control group. Methods: A cross-sectional study was conducted, including adults with T1D and a diabetes duration of >10 years, and age- and body mass index (BMI)-matched healthy controls. MASLD was assessed using vibration-controlled transient elastography. Steatosis was indicated by a controlled attenuation parameter ≥280 dB/m and fibrosis was indicated by a liver stiffness measurement (LSM) ≥8 kPa. Results: We included 85 PWT1D (48.2% female, mean age 47.7 ± 12 years, diabetes duration 28 ± 8 years, BMI 28.4 ± 4.6 kg/m²) and 79 healthy controls (68.4% female, mean age 48.2 ± 11 years, BMI 28 ± 6 kg/m²). In the PWT1D group, higher values were observed for the hepatic steatosis index [37.3 (34-42)], hepamet fibrosis score [0.04 (0-0.1)], NAFLD fibrosis score [-0.8 (-2-0)], and LSM [5.1 (4-6) kPa]. The prevalence of MASLD was 10.9% higher in PWT1D than in healthy controls, while fibrosis was suggested in 13% of PWT1D compared to 2.5% of healthy controls. Conclusion: MASLD was more prevalent in PWT1D compared to age- and BMI-matched healthy controls, although only a small proportion of PWT1D exhibited significant fibrosis.